Search Results - "Vida, John"

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC by Gandhi, Leena, Rodgríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, Angelis, Flávia De, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John J, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C

“…Abstract Background: The premise that chemotherapy and immunotherapy may provide greater benefit than pembro or chemotherapy alone was supported by KEYNOTE-021…”
Get full text

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer by Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y.-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M. Catherine, Garassino, Marina C

“…The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival…”
Get full text

Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189 by Hall, Richard Delmar, Gadgeel, Shirish M., Garon, Edward B., Bria, Emilio, Reck, Martin, Vida, John, Zhou, Honghong, Raftopoulos, Harry, Gandhi, Leena

“…Abstract only…”
Get full text